tldrdailynews.com logo
Tag

Epstein Barr Virus

All articles tagged with #epstein barr virus

Dormant viruses wake up in COVID-19 patients, impacting severity and long COVID
health1 day ago

Dormant viruses wake up in COVID-19 patients, impacting severity and long COVID

A year-long study of over 1,150 hospitalized, unvaccinated COVID-19 patients found that about 48% experienced reactivation of dormant viruses, notably Epstein-Barr virus and cytomegalovirus, with reactivations linked to greater acute severity and higher 1-year mortality in the critically ill; reactivation of Anelloviridae during recovery was associated with long COVID fatigue and disability. The study does not prove causation and has limitations (older SARS-CoV-2 strains, no vaccination status, sampling constraints), but suggests viral reactivation could influence COVID-19 outcomes and may inform risk assessment and future therapies pending further research.

via AOL.com|
#covid-19#cytomegalovirus#epstein-barr-virus
Severe COVID-19 May Wake Hidden Viruses, Study Shows
science12 days ago

Severe COVID-19 May Wake Hidden Viruses, Study Shows

A Nature study of 1,154 hospitalized COVID-19 patients across the U.S. and Canada found 11 dormant viruses reactivated within 40 days of admission, including herpes viruses (Epstein–Barr virus, cytomegalovirus) and Anelloviridae; reactivation appeared linked to inflammation and severe illness, with Anelloviridae reactivation associated with long‑term disability and long COVID, though causality is not proven. The findings may inform future diagnostics and treatments, but applicability to milder cases remains uncertain.

via Yahoo News UK|
#covid-19#epstein-barr-virus#herpes-viruses
Severe COVID-19 May Unleash Dormant Viruses, Study Finds
science14 days ago

Severe COVID-19 May Unleash Dormant Viruses, Study Finds

A multi-center study of 1,154 hospitalized COVID-19 patients over a year found reactivation of 11 dormant viruses within the first 40 days of admission, including Epstein-Barr virus, cytomegalovirus, herpes simplex virus-1, and Anelloviridae. Reactivation appeared linked to inflammation rather than immune suppression and was also associated with long-COVID and long-term disability in some cases, though causation was not established. The findings shed light on how severe COVID-19 can impact the body’s virome and may inform future diagnostics and treatments, especially for those with severe disease.

via Yahoo|
#anelloviridae#covid-19#cytomegalovirus
Antibody Breakthrough Blocks Epstein-Barr Virus in Mice, Could Aid Transplant Patients
science3 months ago

Antibody Breakthrough Blocks Epstein-Barr Virus in Mice, Could Aid Transplant Patients

Epstein-Barr virus (EBV) infects about 95% of adults and can persist for life, with links to cancers and other complications. A team from Fred Hutchinson Cancer Center and the University of Washington developed human-like antibodies targeting EBV surface proteins gp350 and gp42, isolating 10 candidates. In mice with humanized immune systems, one antibody provided protection against EBV, demonstrating a new approach to prevent infection and reactivation. The work could help immunosuppressed transplant patients by reducing EBV-related complications (PTLD), but human safety testing and clinical trials are still needed. Published in Cell Reports Medicine (2026).

via ScienceAlert|
#antibodies#epstein-barr-virus#gp350
Antibody therapy blocks Epstein-Barr virus, paving way for transplant-preventive treatment
health-and-medicine4 months ago

Antibody therapy blocks Epstein-Barr virus, paving way for transplant-preventive treatment

Researchers at Fred Hutchinson Cancer Center developed human-like monoclonal antibodies in a mouse model that block EBV from attaching to and entering B cells, with one gp42-targeting antibody fully preventing infection in humanized mice; the approach could become a preventive therapy to reduce EBV-related disease, including PTLD, in transplant patients, given that EBV infects about 95% of people worldwide. Next steps include safety testing and clinical trials.

via ScienceDaily|
#epstein-barr-virus#gp350#gp42
Antibody Strategy Targets Epstein-Barr Virus to Shield Transplant Patients
science6 months ago

Antibody Strategy Targets Epstein-Barr Virus to Shield Transplant Patients

Fred Hutch researchers produced fully human monoclonal antibodies against EBV by targeting its gp350 and gp42 proteins. In humanized mice, one antibody completely prevented EBV infection and another offered partial protection, outlining a pathway to prevent EBV reactivation and PTLD in transplant patients. The team aims to advance safety testing in healthy volunteers followed by trials in immunocompromised individuals, with IP protection filed for the antibodies.

via SciTechDaily|
#epstein-barr-virus#gp350#gp42
science6 months ago

Human genetics shape persistent Epstein-Barr virus control and autoimmune risk

A large-scale study using UK Biobank and All of Us genome data detects EBV reads in a subset of individuals, linking higher EBV load to HIV, immunosuppression, and smoking; GWAS identifies major associations in MHC/HLA and additional loci including ERAP2, with EBV load polygenic burden tied to multiple sclerosis (MHC class I) and rheumatoid arthritis (MHC class II) and overlaps with inflammatory diseases like IBD, hypothyroidism, and type 1 diabetes; proposes host-genome–derived markers of EBV persistence to guide future research and therapy.

via Nature|
#epstein-barr-virus#erap2#genome-wide-association-study
Biobank DNA leftovers unlock secrets of Epstein–Barr virus
genomics6 months ago

Biobank DNA leftovers unlock secrets of Epstein–Barr virus

Researchers show that non-human DNA discarded during whole-genome sequencing can be repurposed to detect and quantify Epstein–Barr virus DNA in human cells, using a method described by Nyeo et al. in Nature. This population-scale approach lets biobanks reveal persistent EBV DNA and its links to complex diseases, turning sequencing byproducts into a new source of epidemiological insight.

via Nature|
#biobanks#epstein-barr-virus#genomics
"EBV Reactivation Linked to MS Activity and Potential Treatments"
health2 years ago

"EBV Reactivation Linked to MS Activity and Potential Treatments"

A study published in Nature Microbiology found that the dormant Epstein-Barr virus (EBV) reactivates during multiple sclerosis (MS) relapses, triggering inflammatory activity in immune cells. Blocking EBV activation with antiviral compounds like tenofovir alenfenamide (TAF) can reduce this inflammation, suggesting a potential new treatment strategy for MS. However, further research is needed to confirm these findings in human models.

via Multiple Sclerosis News Today|
#antiviral-treatment#epstein-barr-virus#health